India at a glance
- Population
- 1.46 billion 2025
- Life expectancy at birth
- 72.2 years, 2024
- People aged 65 and over
- 7.4 % of people, 2025
- Health spending per person
- 85 US$ per person, 2023
- Doctors
- 0.72 per 1,000 people, 2020
Updated
Reviewed by Chandani Patel
India Eosinophilic Esophagitis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$174.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $26.9 Mn | — | — |
| 2025 (base) | $33.0 Mn | +$6.1 Mn | — |
| 2026 (forecast) | $40.5 Mn | +$7.5 Mn | +22.7% |
| 2027 (forecast) | $49.6 Mn | +$9.2 Mn | +50.6% |
| 2028 (forecast) | $60.9 Mn | +$11.3 Mn | +84.7% |
| 2029 (forecast) | $74.7 Mn | +$13.8 Mn | +126.7% |
| 2030 (forecast) | $91.7 Mn | +$17.0 Mn | +178.1% |
| 2031 (forecast) | $112.5 Mn | +$20.8 Mn | +241.2% |
| 2032 (forecast) | $138.1 Mn | +$25.5 Mn | +318.7% |
| 2033 (forecast) | $169.4 Mn | +$31.3 Mn | +413.8% |
| 2034 (forecast) | $207.8 Mn | +$38.5 Mn | +530.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $33.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $207.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 22.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, age and end user (see all) |
| Key players | Sanofi, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company Ltd, Dr. Falk Pharma, Ellodi Pharmaceuticals (see all) |
| Regulator in India | CDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Eosinophilic esophagitis treatments calm an allergic inflammation of the food pipe that makes swallowing hard.
Key segments of the eosinophilic Esophagitis Treatment market include treatment (Biologics, Topical Steroids and Proton Pump Inhibitors) and age (Children and Adults).
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the eosinophilic Esophagitis Treatment market.
Microbiome-based treatments, earlier testing and digital gut-health programmes give the eosinophilic Esophagitis Treatment market room to grow.
Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the eosinophilic Esophagitis Treatment market.
The eosinophilic Esophagitis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.[2]
[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for eosinophilic Esophagitis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.
What doctors and scientists are doing in Eosinophilic Esophagitis Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.
From our blog
India · 4 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
Medical Devices · India
OTC & Nutraceuticals · India
Medical Devices · India
Public Health · India
Medical Devices · India
Public Health · India